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Introduction
The possibility to desensitize or induce a state of unrespon-
siveness to a drug that previously caused a hypersensitivity
reaction is crucial when no equally safe or efficacious ther-
apeutic alternative exists. The authors report the case of a
successful desensitization to ganciclovir.
Case report
Hospitalized HIV-infected woman, 49 years-old, with
AIDS, presenting with an active cytomegalovirus (CMV)
gastrointestinal infection. On the second day of therapy
with intravenous ganciclovir (250 mg, q12h), the patient
developed an isolated pruriginous maculopapular
exanthema localized to the torso and limbs. A hypersen-
sitivity reaction to ganciclovir was suspected; by this
time, all the other comorbidities were controlled and the
decision to stop the drug was taken. Because the cuta-
neous lesions persisted for some time although on anti-
histaminic and corticosteroid, an alternative treatment to
CMV - foscarnet - was initiated. Biopsy of the skin
lesions was performed with a positive identification of
CMV. Due frequent association of foscarnet to nephro-
toxicity, reintroduction of ganciclovir was attempted on
the sixth day of therapy, using a modified desensitization
protocol based on a previously published protocol for
rapid desensitization to chemotherapy. On the first day, a
cumulative dose of 125 mg was reached in 13 steps, with-
out reactions. On the next day, adding two steps to the
protocol, a dose of 250mg was safely administered. Dose
increments between steps were relatively small, in an
attempt to minimize the risk of reaction. The association
of foscarnet and 250mg of ganciclovir was maintained for
four days. The total daily therapeutic dose (500mg) of
ganciclovir was reached under supervised slow perfusion
(over 90 minutes) of 250mg every 12 hours. No clinical
or analytical reactions were reported so foscarnet could
be suspended, keeping intravenous ganciclovir as
monotherapy. After two weeks under full intravenous
dose, the switch to oral treatment with valganciclovir was
well tolerated.
Comments
To our knowledge, there are no published protocols of
desensitization to ganciclovir. As viral infections might
increase the risk of hypersensitivity reactions, treatment
with foscarnet was maintained until the therapeutic
dose of ganciclovir was reached, assuring full CMV
treatment along all the process.
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